Future Farm Partners with Israeli Company to Develop Elite Cannabis Clones
November 17th, 2017
Exclusive, News, Top Story
The cannabis industry is expected to experience a significant growth spurt next year following the legalization of recreational cannabis in California and across Canada. While the industry should see significant demand, many companies still struggle to produce reliable products in terms of cannabinoid, terpene, and flavonoid profiles. Cloning technology could help address many of these problems by creating genetically-identical cannabis plants.
What are Cannabis Clones?
The most common way to breed cannabis plants is to cross a male and a female plant through pollination to create seeds. Since these seeds are a genetic hybrid of both parents, they don’t necessarily have the same characteristics. This creates a problem in the medical cannabis industry where researchers rely on stable concentrations of cannabinoids, terpenes, and flavonoids to deliver a consistent therapeutic benefit to patients.
Clones are tissue cultured produced plants that are genetically identical to the plant from which they were taken. In its most basic form, clones are simply branches that are cut from the parent plant that eventually grow roots of their own. The benefit is that growers can create exact replicas of their best performing plants that will have the same characteristics, while they don’t need to spend the time and money needed to pop new seeds.
Industrial scale cannabis cloning enables growers to access specific cannabis strains that have ideal concentrations of cannabinoids like tetrahydrocannabinol (THC) and cannabidiol (CBD). Rather than buying seeds and taking a gamble, these growers can be certain that they’re getting exactly what they want in terms of the plant’s characteristics. They can then reliably produce extracts and other products from these plants over time.
Rahan Leads the Market
The cloning process may be relatively simple in its most basic form, but mass-scale cloning requires significant technology and expertise. Rahan Meristem Ltd. is a world-renowned global agro-biotechnology company that has established itself as an expert in the space. With more than 250 employees across five locations, the company produces millions of plants each year that are exported to more than 20 countries around the world. It is also conveniently headquartered in Israel, which is in many ways the epicenter of cutting edge cannabis research.
For example, the company has recently worked with Evogene Ltd. (NASDAQ: EVGN) to develop banana plants that are resistant to Black Sigatoka disease. Evogene contributed the genome editing technology and Rahan contributed its propagation know-how and massive seeding production lines that could bring the breakthrough to scale. The company works with a number of partners like these to develop breakthrough plant clones.
In addition to its mass production capabilities, Rahan specializes in molecular and classical genetics, plant cell and tissue cultures, plant biochemistry and physiology, and industrial biotechnology. This means that the company has the personnel and technology to help not only mass produce clones, but optimize their genetics to meet end market needs. It is also important to note that Rahan’s approach to maximizing and refining genetics does not produce plants that are labeled GMO, or Genetically Modified Organisms.
Promising Joint Venture
Future Farm Technologies Inc. (CSE: FFT) (OTCQB: FFRMF) recently announced a new 50/50 joint venture with Rahan Meristem Ltd. Under the agreement, Future Farm will provide funding and an indoor, air conditioned laboratory in the United States or Canada and Rahan will contribute its proven and proprietary technology to mass produce elite clones of cannabis and hemp plants that can be sold for medical purposes around the world.
“We are thrilled to partner with Rahan Meristem, an esteemed leader in the agro-biotechnology industry,” said Future Farm Technologies CEO Bill Gildea. “Rahan has shown long term dedication to producing elite clones of bananas, plantains, and other plants for its customers worldwide. We are lucky to have Rahan’s desire to take its proven technology to work on producing the same results for cannabis and hemp.”
A major aspect of the agreement is the 50/50 rights to the Intellectual Property that results from the collaboration. In other words, the plants developed are patentable, and the companies have agreed to share in the profits. The potential end markets are very large, including growers of both hemp and cannabis, biopharmaceutical companies looking to develop drugs, and companies developing nutraceutical and personal care products based on the plant.
Together, the companies should be able to create hyper-specific strains to meet a variety of needs. For example, a pharma company’s research may indicate that a certain mix of cannabinoids and terpenes shows promise for the treatment of a disease indication. That exact mix is not easily produced with more traditional methods of propagation, but Rahan has repeatedly demonstrated the ability to effectively and efficiently create reproducible plant strains with very complex and specific requirements.
Future Farm Technologies Inc.’s (CSE: FFT) (OTCQB: FFRMF) recent deal with Rahan could solidify its leadership position in the cannabis industry. With the potential to become a leading supplier of clones, investors may want to take a closer look at the stock ahead of recreational legalization in California and Canada next year. Demand for reliable, standardized cannabis clones should continue to grow alongside the overall market.
For more information, visit the company’s website at www.futurefarmtech.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.